Back

Aspirin desensitization in patients with coronary artery disease: results of a multicenter registry

29 August 2016 (11:36 - 11:45)
Organised by:
Congress Presentation Part of: Clinical studies on platelet inhibition Thrombosis and platelets ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Roberta Rossini

Santa Croce E Carle Hospital, Cuneo (Italy)

9 More presentations in this session

Presentation thumbnail
Incidence of colorectal cancer in new users and non-users of low-dose aspirin for primary prevention of cardiovascular or cerebrovascular disease in the United Kingdom
Doctor L. Garcia Rodriguez (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Short versus prolonged dual antiplatelet therapy duration after bare-metal stent implantation: 2-month landmark analysis from the Credo-Kyoto registry cohort-2
Doctor M. Natsuaki (Saga, JP)
Abstract Slides Video
Presentation thumbnail
Clinical implications of low-dose aspirin in vasospastic angina : the 3-year prognosis
Doctor Y. Lee (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Validation of the DAPT score in the all comer PRODIGY trial
Doctor R. Piccolo (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Ticagrelor reduces the risk of ischemic stroke after acute myocardial infarction compared with clopidogrel
Mr R. Henriksson (Umea, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Clinical studies on platelet inhibition

The Event

Event poster

ESC Congress 2016

29 August 2016 11:36 CET
You may be interested in
thumbnail
Congress Presentation
Acetylsalicylic acid challenge or desensitization in sensitive patients with cardiovascular disease
25 August 2023
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
19 July 2023
thumbnail
Congress Presentation
Residual platelet activity and systemic inflammation in patients with chronic coronary syndrome in the context of aspirin monotherapy.
29 June 2021
thumbnail
Congress Presentation
Feasibility and outcomes of tailored antiplatelet therapy at a safety-net hospital
21 March 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources